Skip to main content

Table 3 Relation between chief complaints and clinical features

From: The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study

 

Complaint with/without weakness

Complaint with/without numbness

 

with

Without

P value

with

without

P value

Basic information

 Number of patient

384

139

 

161

362

 

 Male/female ratio

234/150

77/62

.23

90/71

222/140

.23

 Age, median (IQR)

39 (29–48)

47 (34.25–58.75)

.042

41 (31–56)

40 (29.5–50)

.30

Antecedent infection

 Diarrhea, No. (%)

111 (28.80)

27 (19.59)

.031

36 (22.64)

100 (27.75)

.21

 Upper respiratory tract infection, No. (%)

103 (26.93)

49 (35.14)

.063

64 (39.62)

90 (24.73)

.001

Clinical manifestations

 Cranial nerve involvement, No. (%)

152 (39.49)

79 (56.72)

< .001

82 (50.76)

157 (43.26)

< .001

 Hyporeflexia, No. (%)

361 (94.03)

119 (85.96)

.002

99 (61.24)

134 (37.02)

< .001

 Sensory deficits, No. (%)

160 (41.67)

65 (46.58)

.34

94 (58.22)

132 (36.39)

< .001

 Autonomic deficits, No. (%)

200 (52.00)

88 (63.51)

.017

97 (60.38)

192 (53.02)

.14

 Dyspnea, No. (%)

101 (26.40)

33 (23.65)

.16

32 (20.13)

101 (28.02)

.053

 Ventilator dependence, No. (%)

46 (12.00)

18 (12.84)

.79

14 (8.81)

46 (12.74)

.11

Severity of disease

 MRC sum score at admission, median (IQR)

45 (32.75–52)

47 (37.5–56)

< .001

48 (42–56)

42.5 (31.25–51.5)

< .001

 HFGS at admission, median (IQR)

4 (2.75–4)

3 (1.75–4)

< .001

3 (2–4)

4 (2–4)

< .001

 MRC sum score at nadir, median (IQR)

42 (28–48.25)

42 (34–54.5)

< .001

46 (36–54)

36 (21–48)

< .001

 HFGS at nadir, median (IQR)

4 (3–4)

3.5 (2–4)

.001

3 (3–4)

4 (3–4)

< .001

 MRC sum score at discharge, median (IQR)

54 (44–57.25)

54 (42–60)

.002

55 (48–60)

48.5 (36.5–58)

< .001

 HFGS as discharge, median (IQR)

2 (2–4)

1 (0–1.25)

.002

2 (1–3.75)

3 (1–4)

.009